The Biosimilar Red Tape Elimination Act is designed to simplify the approval process for biosimilar biological products, which are medications similar to already approved reference products. The primary goal of this legislation is to facilitate easier market entry for biosimilars, thereby increasing competition and ultimately lowering drug prices for consumers. The Act introduces several key provisions that modify the application process for biosimilars. It removes outdated requirements that previously complicated the path to achieving interchangeable status for these products.